- In February 2025, Mitsubishi Tanabe Pharma launched a new topical therapy for localized scleroderma in Europe.
- In January 2025, Roche expanded its Actemra (tocilizumab) scleroderma study to multiple European clinical sites.
- In October 2024, a multicenter trial evaluating sildenafil for digital ulcers in systemic sclerosis was initiated in Germany and Spain.
- In March 2025, Pfizer Inc. collaborated with European Scleroderma Trials and Research group (EUSTAR) to launch a real-world evidence study evaluating immunosuppressant use in systemic sclerosis.
- In April 2025, Roche initiated a Phase II trial across Germany, France, and Italy for a novel antifibrotic monoclonal antibody targeting scleroderma-associated lung fibrosis.
